SCHEMBL10169191

SCHEMBL10169191

Cc1ccc(C(N)=O)c(Nc2ccccc2)n1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 3/20 0.54
RAB9A P51151 2/20 0.51
NPC1 O15118 1/20 0.51
MAPT P10636 1/20 0.51
AHR P35869 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
SYK P43405 3/20 0.50
ZAP70 P43403 1/20 0.50
MAPK9 P45984 2/20 0.48
KDM4E B2RXH2 1/20 0.47
CYP1A2 P05177 1/20 0.47
PDE4B Q07343 4/20 0.46
PARP1 P09874 1/20 0.46
GAA P10253 1/20 0.45
KMT2A Q03164 1/20 0.45
TGFBR1 P36897 1/20 0.44
STAT6 P42226 1/20 0.44
EGFR P00533 1/20 0.44
FER P16591 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8171612 0.87 DHODH (0.57) RAB9ANPC1MAPTSMN1; SMN2PDE4B
SCHEMBL846982 0.86 MAPT (0.44) MAPK8RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL12715339 0.83 MAPT (0.54) MAPK8RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL10169198 0.82 NPC1 (0.47) MAPK8RAB9ANPC1MAPTAHR
SCHEMBL14617173 0.82 GAA (0.46) MAPK8RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL10169304 0.81 SYK (0.52) RAB9ANPC1MAPTAHRSMN1; SMN2
SCHEMBL10169201 0.79 SYK (0.51) MAPK8RAB9ANPC1MAPTAHR
SCHEMBL10169400 0.78 LMNA (0.48) NPC1MAPTSMN1; SMN2KMT2A
SCHEMBL22093021 0.78 MAPK8 (0.51) MAPK8SYKZAP70MAPK9PDE4B
SCHEMBL14617172 0.77 ALDH1A1 (0.39) MAPK8RAB9ANPC1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8586751-B2 Nicotinamide compounds useful as kinase modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2013-11-19 US disclosed
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MEYERS SQUIBB COMPANY 2012-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS NADK, BTK, NAMPT MAPK8 223/4885RAB9A 1841/4885NPC1 1778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.